MétaCan
Menu
Back to cohort
Record W2475786228 · doi:10.1056/nejmoa1602489

Randomized Trial of Thymectomy in Myasthenia Gravis

2016· article· en· W2475786228 on OpenAlexafffund
Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban, Greg Minisman, Hui‐Chien Kuo, Alexander Marx, Philipp Ströbel, Claudio Mazia, Joël Oger, Gabriel Cea, Jeannine M. Heckmann, Amelia Evoli, Wilfred A. Nix, Emma Ciafaloni, Giovanni Antonini, Rawiphan Witoonpanich, John King, Said R. Beydoun, Colin Chalk, Alexandru Barboi, Anthony A. Amato, Aziz Shaibani, Bashar Katirji, Bryan Lecky, Camilla Buckley, Angela Vincent, Elza Dias‐Tosta, Hiroaki Yoshikawa, Márcia Waddington‐Cruz, Michael Pulley, Michael H. Rivner, Anna Kostera‐Pruszczyk, Robert M. Pascuzzi, Carlayne E. Jackson, Guillermo Ramos, Jan J.G.M. Verschuuren, Janice M. Massey, John T. Kissel, Lineu César Werneck, Michael Benatar, Richard J. Barohn, Rup Tandan, Tahseen Mozaffar, Robin Conwit, Joanne Odenkirchen, Joshua Sonett, Alfred Jaretzki, John Newsom–Davis, Gary Cutter

Post-publication record

NatureCorrection
ReasonError in Methods;Error in Results and/or Conclusions;
Date5/25/2017 0:00
Flagged by OpenAlex?No. Retraction Watch records this, and OpenAlex does not flag it.

Source: Retraction Watch, joined by DOI. OpenAlex records retraction as is_retracted, a boolean over a state space with at least four values, so it cannot express an expression of concern, a correction or a reinstatement; it reports them as false, which reads as “fine”.

Bibliographic record

VenueNew England Journal of Medicine · 2016
Typearticle
Languageen
FieldMedicine
TopicMyasthenia Gravis and Thymoma
Canadian institutionsMcGill UniversityUniversity of British Columbia
FundersNational Institute of Neurological Disorders and StrokeGenentechNational Institutes of HealthGrifolsEMD SeronoGaldermaArgenxMallinckrodt PharmaceuticalsAstellas PharmaMomenta PharmaceuticalsIonis PharmaceuticalsChugai PharmaceuticalHorizon PharmaCSL BehringBaxaltaQuestcor PharmaceuticalsPfizerBiogenPTC TherapeuticsCelgeneAlexion PharmaceuticalsTeva Pharmaceutical IndustriesAlnylam PharmaceuticalsGilead SciencesUniversity of PennsylvaniaMuscular Dystrophy AssociationSanofiSavara PharmaceuticalsGlaxoSmithKlineMyasthenia Gravis Foundation of America
KeywordsThymectomyPrednisoneMyasthenia gravisMedicineAzathioprineRandomized controlled trialImmunosuppressionRandomizationSurgeryInternal medicineGastroenterologyDisease

Abstract

fetched live from OpenAlex

BACKGROUND: Thymectomy has been a mainstay in the treatment of myasthenia gravis, but there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial comparing thymectomy plus prednisone with prednisone alone. METHODS: We compared extended transsternal thymectomy plus alternate-day prednisone with alternate-day prednisone alone. Patients 18 to 65 years of age who had generalized nonthymomatous myasthenia gravis with a disease duration of less than 5 years were included if they had Myasthenia Gravis Foundation of America clinical class II to IV disease (on a scale from I to V, with higher classes indicating more severe disease) and elevated circulating concentrations of acetylcholine-receptor antibody. The primary outcomes were the time-weighted average Quantitative Myasthenia Gravis score (on a scale from 0 to 39, with higher scores indicating more severe disease) over a 3-year period, as assessed by means of blinded rating, and the time-weighted average required dose of prednisone over a 3-year period. RESULTS: A total of 126 patients underwent randomization between 2006 and 2012 at 36 sites. Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in the thymectomy group also had a lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001). Fewer patients in the thymectomy group than in the prednisone-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized for exacerbations (9% vs. 37%, P<0.001). The number of patients with treatment-associated complications did not differ significantly between groups (P=0.73), but patients in the thymectomy group had fewer treatment-associated symptoms related to immunosuppressive medications (P<0.001) and lower distress levels related to symptoms (P=0.003). CONCLUSIONS: Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis. (Funded by the National Institute of Neurological Disorders and Stroke and others; MGTX ClinicalTrials.gov number, NCT00294658.).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.027

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.007
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.289
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations905
Published2016
Admission routes2
Has abstractyes

Explore more

Same venueNew England Journal of MedicineSame topicMyasthenia Gravis and ThymomaFrench-language works237,207